5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in
the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than
12 months of age compared to topical corticosteroids (TCS).